Tildrakizumab for the treatment of psoriasis. (21st September 2018)

• Record Type: Journal Article
• Authors: Bangert, Christine; Kopp, Tamara
• Is Part Of: Immunotherapy. Volume 10:Number 13(2018)
• Page Start: 1105
• Page End: 1122
• Publication Date: 2018-09-21
• Subjects: biologic therapy -- IL-23p19 -- psoriasis -- tildrakizumab -- Th17; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2018-0028
• Languages: English
• ISSNs: 1750-743X

Abstract

Psoriasis is a chronic skin disorder driven by IL-23 and the downstream T-helper cell 17 (Th17) pathway. Tildrakizumab is a humanized monoclonal antibody selectively targeting the p19 subunit of IL-23, a key cytokine for Th17 cells. Here, we provide an overview of IL-23 in the context of psoriasis pathogenesis and review the results of the Phase I, II and III clinical trials for tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis in order to assess its efficacy, safety and clinical usefulness. In all clinical trials, tildrakizumab demonstrated significant clinical improvement and a favorable safety profile. In Phase III trials, 75% of tildrakizumab-treated patients reached a Psoriasis Area and Severity Index 75 at week 28 demonstrating superior efficacy as compared with etanercept treatment. The tildrakizumab-induced reduction in skin inflammation proves the important pathogenic role of IL-23 in psoriasis and further supports the utility of drugs targeting the IL-23/Th17 pathway. Targeting IL-23p19 with tildrakizumab augments the therapeutic repertoire for patients with moderate-to-severe chronic plaque psoriasis.